Deepmatter, now ChemAI, unveils its strategic rebrand and board changes.
- The rebrand aligns with ChemAI’s vision to integrate AI into the future of chemistry.
- Dave Norwood joins as Chairman, enhancing the leadership team.
- Tony de Fougerolles is appointed as Non-Executive Director to bolster the board.
- ChemAI aims to harness AI to transform the chemical and pharmaceutical industries.
Deepmatter, a Leeds-based company, has undergone a significant transformation by rebranding itself as ChemAI. This change is part of a broader strategic plan aimed at integrating artificial intelligence more deeply into the field of chemistry. The rebrand reflects the company’s ambition to redefine the role of data and AI in this sector.
As part of this strategic shift, Dave Norwood has been appointed as the new Chairman of ChemAI. Norwood’s background includes founding IP Group PLC and Oxford Science Enterprises, organisations which have played pivotal roles in advancing technology investments, particularly in Oxford. He also played a key role in the establishment of Oxford Nanopore, known for its advances in DNA sequencing.
Additionally, Tony de Fougerolles joins the board as a Non-Executive Director. De Fougerolles brings over 25 years of experience in biotechnology research and development. Previously, he served as CEO of Evox Therapeutics. He expressed enthusiasm about joining ChemAI, noting the potential of its AI-driven platform to significantly enhance innovation and efficiency in the chemical sector.
ChemAI is not only rebranding but also expanding its reach across Europe, with offices located in Leeds, Glasgow, Munich, and Lyon. The company focuses on developing and marketing AI tools designed to assist chemists. A key strength of ChemAI’s AI systems is their foundation on a proprietary database which now encompasses over 23 million chemical reactions.
The leadership emphasises that while ChemAI’s AI tools are transformative, they are not meant to replace chemists. Instead, the goal is to make chemists using these tools more productive and creative than ever before. This forward-thinking approach aims to unlock new opportunities within the chemical and pharmaceutical industries.
ChemAI’s rebrand and leadership changes strategically position the company to revolutionise chemistry with AI.
